Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Cardio Diagnostics Epi+Gen CHD Launches

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Cardio Diagnostics Epi+Gen CHD test sensitively assesses the risk for the onset of new coronary heart disease, an ability that is key to providing cost-effective health care for adults.

Despite the importance of preventative health in cardiovascular disease, for the past 30 years, clinicians have had to rely on insensitive, mono-dimensional methods for guiding preventative care. Primary care clinicians currently have only two tools: the Framingham Risk Score (FRS), and the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator, for predicting future heart disease. “Unfortunately, in both research settings and in real-world practice, these tools perform poorly,” said Robert Philibert MD Ph.D., Co-Founder and Chief Medical Officer of Cardio Diagnostics.

Cardio Diagnostics has developed Epi+Gen CHD, an alternative to the existing tests on the market. Epi+Gen CHD not only predicts who is at lower risk of developing coronary heart disease, which current tests do well, but also identifies who is at higher risk of developing coronary heart disease, which current tests do not do well. Cardio Diagnostics’ flagship product focuses on risk for coronary heart disease because it is the most common type of heart disease, and the major cause of heart attacks.

“In particular, both the FRS and ASCVD risk calculator are relatively insensitive to the new onset of cardiovascular disease in women and minorities. We are hopeful that our new test will lead to a reduction in fatal heart attacks and to the discovery of even better methods to diagnose, treat and prevent heart disease,” said Dr. Philibert.

Cardio Diagnostics’ Chief Executive Officer and Co-Founder, Meeshanthini (Meesha) Dogan Ph.D., shared “we are incredibly excited about getting this early risk assessment test to the market. As the first integrated and more sensitive genetic-epigenetic clinical test for assessing the three-year risk for a heart attack, Epi+Gen CHD is the future of preventative cardiovascular disease care. Cardio Diagnostics uses the latest breakthroughs in Epigenetics and Artificial Intelligence/Machine Learning to begin an era of better preventative heart care, and I am proud of what we’ve built,” Dr. Dogan said.

She added that “because Epi+Gen CHD leverages telemedicine and at-home sampling, even with the ongoing pandemic, it will allow patients to continue prioritizing prevention from the comfort and privacy of their own home with guidance from a clinician. This is important for those concerned about potential for Covid-19 exposure. We have a great team and are working to close our financing round in early 2021, expand key partnerships while adding new members to our team and advisory board.”

 

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine